Last reviewed · How we verify

Veligrotug (VRDN-001)

Viridian Therapeutics, Inc. · Phase 3 active Small molecule

Veligrotug (VRDN-001) is a Thyroid hormone receptor beta (THR-β) agonist Small molecule drug developed by Viridian Therapeutics, Inc.. It is currently in Phase 3 development for Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk.

Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.

Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides. Used for Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk.

At a glance

Generic nameVeligrotug (VRDN-001)
SponsorViridian Therapeutics, Inc.
Drug classThyroid hormone receptor beta (THR-β) agonist
TargetThyroid hormone receptor beta (THR-β)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

THR-β agonists preferentially activate the beta isoform of the thyroid hormone receptor, which is highly expressed in the liver and plays a key role in lipid metabolism. By selectively activating THR-β, veligrotug increases the clearance of LDL cholesterol and reduces triglyceride levels while minimizing systemic thyroid hormone effects that could cause cardiac or metabolic side effects associated with non-selective thyroid hormone therapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Veligrotug (VRDN-001)

What is Veligrotug (VRDN-001)?

Veligrotug (VRDN-001) is a Thyroid hormone receptor beta (THR-β) agonist drug developed by Viridian Therapeutics, Inc., indicated for Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk.

How does Veligrotug (VRDN-001) work?

Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.

What is Veligrotug (VRDN-001) used for?

Veligrotug (VRDN-001) is indicated for Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk.

Who makes Veligrotug (VRDN-001)?

Veligrotug (VRDN-001) is developed by Viridian Therapeutics, Inc. (see full Viridian Therapeutics, Inc. pipeline at /company/viridian-therapeutics-inc).

What drug class is Veligrotug (VRDN-001) in?

Veligrotug (VRDN-001) belongs to the Thyroid hormone receptor beta (THR-β) agonist class. See all Thyroid hormone receptor beta (THR-β) agonist drugs at /class/thyroid-hormone-receptor-beta-thr-agonist.

What development phase is Veligrotug (VRDN-001) in?

Veligrotug (VRDN-001) is in Phase 3.

What are the side effects of Veligrotug (VRDN-001)?

Common side effects of Veligrotug (VRDN-001) include Increased heart rate, Thyroid hormone-related effects.

What does Veligrotug (VRDN-001) target?

Veligrotug (VRDN-001) targets Thyroid hormone receptor beta (THR-β) and is a Thyroid hormone receptor beta (THR-β) agonist.

Related